Related references
Note: Only part of the references are listed.Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial
M. Goebeler et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
Efgartigimod: First Approval
Young-A Heo
DRUGS (2022)
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies
Chiara Briani et al.
NEUROTHERAPEUTICS (2022)
Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study
Chong Yan et al.
NEUROLOGY AND THERAPY (2022)
Antibodies to watch in 2021
Helene Kaplon et al.
MABS (2021)
Comparison of Phenotypic Characteristics and Prognosis Between Black and White Patients in a Tertiary ALS Clinic
David Brand et al.
NEUROLOGY (2021)
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Anil Gupta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease
Wei Sun et al.
MOLECULAR THERAPY (2021)
In Translation: FcRn across the Therapeutic Spectrum
Timothy Qi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The Dual Targeting of FcRn and FcγRs via Monomeric Fc Fragments Results in Strong Inhibition of IgG-Dependent Autoimmune Pathologies
Celine Monnet et al.
FRONTIERS IN IMMUNOLOGY (2021)
Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial
Luis Puig et al.
DERMATOLOGY AND THERAPY (2021)
Ways in which the neonatal Fc-receptor is involved in autoimmunity
Juliette Lamamy et al.
JOURNAL OF TRANSLATIONAL AUTOIMMUNITY (2021)
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis A Phase 2 Randomized Control Trial
Vera Bril et al.
NEUROLOGY (2021)
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria
Alexander Roeth et al.
BLOOD (2020)
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Anthony Traboulsee et al.
LANCET NEUROLOGY (2020)
Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fcγ receptors
Anthony Shock et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
M. Pamela Griffin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations
Hans-Hartmut Peter et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
The Neonatal Fc Receptor (FcRn): A Misnomer?
Michal Pyzik et al.
FRONTIERS IN IMMUNOLOGY (2019)
Dual Function pH Responsive Bispecific Antibodies for Tumor Targeting and Antigen Depletion in Plasma
Jan P. Bogen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Next-generation Fc receptor-targeting biologics for autoimmune diseases
Adrian W. Zuercher et al.
AUTOIMMUNITY REVIEWS (2019)
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study
Leona E. Ling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Engineered pH-dependent recycling antibodies enhance elimination of Staphylococcal enterotoxin B superantigen in mice
Andrew Kroetsch et al.
MABS (2019)
M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model
Sucharita Roy et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2019)
Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses
L. J. Blumberg et al.
SCIENCE ADVANCES (2019)
Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics
Nicole M. Piche-Nicholas et al.
MABS (2018)
Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
Douglas Sheridan et al.
PLOS ONE (2018)
In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor
Johan Seijsing et al.
SCIENTIFIC REPORTS (2018)
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Peter Ulrichts et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration
Bryan Smith et al.
MABS (2018)
Targeting FcRn to Generate Antibody-Based Therapeutics
E. Sally Ward et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
The SMART Anti-hC5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alexander Roeth et al.
BLOOD (2018)
Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption
Rafal Swiercz et al.
ONCOTARGET (2017)
Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody
Jon A. Kenniston et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn
Danlin Yang et al.
MABS (2017)
Autoimmune Hemolytic Anemia
Howard A. Liebman et al.
MEDICAL CLINICS OF NORTH AMERICA (2017)
Engineered clearing agents for the selective depletion of antigen-specific antibodies
Siva Charan Devanaboyina et al.
NATURE COMMUNICATIONS (2017)
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
Anne Zufferey et al.
JOURNAL OF CLINICAL MEDICINE (2017)
Effects of SA237, a humanized anti-interleukin-6 receptor monoclonal antibody, on pre- and postnatal development in cynomolgus monkey
Ryuichi Katagiri et al.
BIRTH DEFECTS RESEARCH (2017)
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases
Taku Fukuzawa et al.
SCIENTIFIC REPORTS (2017)
IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding
David Ternant et al.
JOURNAL OF IMMUNOLOGY (2016)
Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis
Emilie Dalloneau et al.
ONCOTARGET (2016)
Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions
Algirdas Grevys et al.
JOURNAL OF IMMUNOLOGY (2015)
Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics
Amita Datta-Mannan et al.
MABS (2015)
Antibody engineering for increased potency, breadth and half-life
Stuart A. Sievers et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Fully human monoclonal antibocy inibitors of the neonatal Fc receptor reduce circulating IgG in non-human primates
Andrew E. Nixon et al.
FRONTIERS IN IMMUNOLOGY (2015)
Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions
Celine Monnet et al.
FRONTIERS IN IMMUNOLOGY (2015)
pH-dependent antigen-binding antibodies as a novel therapeutic modality
T. Igawa et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2014)
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering
Yuan Wang et al.
JOURNAL OF DRUG TARGETING (2014)
Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge
Bing Li et al.
MABS (2014)
An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein
Johan Seijsing et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
Gabriel J. Robbie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Discovery and structure-activity relationships of small molecules that block the human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction
Zhaolin Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Neonatal Fc Receptor Expression in Dendritic Cells Mediates Protective Immunity against Colorectal Cancer
Kristi Baker et al.
IMMUNITY (2013)
The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics
Siva Charan Devanaboyina et al.
MABS (2013)
Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo
Tomoyuki Igawa et al.
PLOS ONE (2013)
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
Inessa Schwab et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
Javier Chaparro-Riggers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences
Weirong Wang et al.
DRUG METABOLISM AND DISPOSITION (2011)
Neonatal Fc receptor and IgG-based therapeutics
Timothy T. Kuo et al.
MABS (2011)
Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-α Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys
Rong Deng et al.
DRUG METABOLISM AND DISPOSITION (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
Enhanced antibody half-life improves in vivo activity
Jonathan Zalevsky et al.
NATURE BIOTECHNOLOGY (2010)
Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates
Yik Andy Yeung et al.
JOURNAL OF IMMUNOLOGY (2009)
Analyses of the Recycling Receptor, FcRn, in Live Cells Reveal Novel Pathways for Lysosomal Delivery
Zhuo Gan et al.
TRAFFIC (2009)
Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn
Adam R. Mezo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Dependence of antibody-mediated presentation of antigen on FcRn
Shuo-Wang Qiao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Monoclonal antibody clearance -: Impact of modulating the interaction of IgG with the neonatal Fc receptor
Amita Datta-Mannan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Albumin binding to FcRn: Distinct from the FcRn-IgG interaction
C Chaudhury et al.
BIOCHEMISTRY (2006)
Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life
B Gurbaxani et al.
MOLECULAR IMMUNOLOGY (2006)
An engineered human IgG1 antibody with longer serum half-life
PR Hinton et al.
JOURNAL OF IMMUNOLOGY (2006)
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
C Vaccaro et al.
NATURE BIOTECHNOLOGY (2005)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Increasing the affinity of a human IgG1, for the neonatal Fc receptor: Biological consequences
WF Dall'Acqua et al.
JOURNAL OF IMMUNOLOGY (2002)
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex:: Mechanism of pH-dependent binding
WL Martin et al.
MOLECULAR CELL (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Engineered antibodies with increased activity to recruit complement
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2001)
Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor
AP West et al.
BIOCHEMISTRY (2000)
Share Paper
